atopic dermatitis

18 · 20 / page

Ask MedXY AI

Latest news

Tag

Allergy & ImmunologyAbrocitinibatopic dermatitis

Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies

By MedXY|Jul 12, 2026

This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their im

Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis

Allergy & Immunology

atopic dermatitis

Latest news

Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies

Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis

Large-Scale Meta-Analysis Finds Higher Influenza and Shingles Risk with JAK-STAT Inhibitors

Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models

Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment

Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis

Bathing Frequency and Eczema Severity: Analysis of the Eczema Bathing Citizen Science Randomized Controlled Trial

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial

Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial

Bridging the Gap: A New Evidence-Based Patient Decision Aid for Systemic Atopic Dermatitis Therapy

Mapping the Atopic Landscape: New Meta-Analysis Identifies Key Drivers and Critical Windows for Childhood Food Allergy

Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial

High-Dose Prenatal Vitamin D and Childhood Atopy: Why Maternal Smoking History Matters

Rocatinlimab (OX40 blockade) delivers clinically meaningful benefit in moderate-to-severe atopic dermatitis: results from ROCKET-IGNITE and ROCKET-HORIZON

SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

Daily Emollient Use in Infants: A Promising Strategy to Prevent Pediatric Atopic Dermatitis